Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Several non-label-related statements (cost/insurance/savings cards) are not supported by the provided FDA label excerpts, and multiple clinical claims are incomplete/overgeneralized relative to labeled indications and administration criteria (e.g., timing, follicular development requirements, and specific patient eligibility).
Category Scores
Accurate Statements
Ovidrel is a form of human chorionic gonadotropin (hCG).
Label excerpt indicates Ovidrel is choriogonadotropin alfa, an hCG product (Section 5 references “Like other hCG products, Ovidrel…”; Section 4 uses hCG-related hypersensitivity language).
Ovidrel is used in fertility treatments.
Section 1 indicates use in ART and ovulation induction (OI) programs in infertile women.
Ovidrel works by stimulating the final maturation of ovarian follicles and triggering the release of an egg.
Section 1 states induction of final follicular maturation and early luteinization; Section 1 also indicates induction of ovulation.
Unsupported Statements
A single Ovidrel pre-filled syringe containing 250 mcg of choriogonadotropin alfa can cost upwards of $100 without insurance.
FDA label excerpts provided do not include any product pricing or cost information.
One source lists a price of $106.23 for a 0.45 mL injection of Ovidrel.
FDA label excerpts provided do not include pricing or market price references.
Insurance plans that cover fertility treatments can reduce out-of-pocket cost of Ovidrel.
FDA label excerpts provided do not include insurance coverage or reimbursement/cost guidance.
The out-of-pocket cost of Ovidrel depends on a person's co-pay, deductible, and co-insurance.
FDA label excerpts provided do not include explanations of out-of-pocket cost structure.
Manufacturers of prescription drugs may offer savings cards or discount programs for eligible patients.
FDA label excerpts provided do not include statements about manufacturer savings cards/discount programs.
Contradictions
Important Omissions
Indication eligibility and prerequisites for ART use are not fully specified: label requires infertile women who have undergone pituitary desensitization and have been appropriately pretreated with follicle stimulating hormones (Section 1).
Importance:
Moderate
Administration timing and follicular development requirements are not specified: label states Ovidrel 250 mcg should be administered one day following the last dose of the follicle stimulating agent and should not be administered until adequate follicular development is indicated by serum estradiol and vaginal ultrasonography; dosing should be withheld for excessive ovarian response (Section 2).
Importance:
High
For anovulatory infertile patients (OI), label specifies indication for functional cause not due to primary ovarian failure; AI claim does not include this qualifier (Section 1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes incomplete/inaccurately generalized dosing/administration context (missing labeled prerequisites and withheld conditions), which could affect appropriate use timing and eligibility; however, no explicit contraindication violations were stated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Clinical use statements omit key labeled eligibility criteria and administration constraints (FSH pretreatment/pituitary desensitization in ART; timing and requirement for adequate follicular development and withholding for excessive ovarian response).
Suggested Improvement
Revise indication and administration statements to reflect Section 1 and Section 2 requirements (patient eligibility qualifiers and specific timing/monitoring and “withhold” criteria). Remove non-label claims about pricing/insurance/savings cards.